Pilot study evaluating the role of cardiac magnetic resonance imaging in monitoring adjuvant trastuzumab therapy for breast cancer

Asia Pac J Clin Oncol. 2012 Mar;8(1):95-100. doi: 10.1111/j.1743-7563.2011.01462.x. Epub 2012 Jan 12.

Abstract

Aim: To explore the incidence of subclinical cardiotoxicity in women treated with adjuvant trastuzumab in the early breast cancer setting using cardiac magnetic resonance imaging (cMRI).

Methods: The cardiac function and myocardial tissue characteristics of 25 women who had completed adjuvant trastuzumab therapy greater than 6 months previously was evaluated using MRI and comparing this with symptoms and routine echocardiography.

Results: Evidence of myocardial tissue damage was seen in two women in the absence of functional change or previous cardiac symptoms.

Conclusion: Tissue characterization using cMRI may provide a useful tool in defining trastuzumab induced cardiotoxicity.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal, Humanized / adverse effects*
  • Antineoplastic Agents / adverse effects*
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / pathology
  • Cardiovascular Diseases / chemically induced*
  • Cardiovascular Diseases / diagnosis*
  • Drug Monitoring
  • Female
  • Humans
  • Magnetic Resonance Imaging*
  • Middle Aged
  • Pilot Projects
  • Receptor, ErbB-2 / immunology
  • Trastuzumab

Substances

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Receptor, ErbB-2
  • Trastuzumab